Abstract: To maintain an almost unchanged plasma-protein profile in a patient subsequent to plasma exchange, the plasma-exchange medium contains the most essential human serum proteins, except for the coagulation factors, at a concentration of 75 g/l.

Abstract: Conjugates of apotransferrin labelled with radioactive iodine are set forth along with a method of tumor imaging, diagnosis and localization using the radioiodinated apotransferrin.

Abstract: Conjugates of transferrin or ceruloplasmin with anti-tumor agents. Such conjugates are useful in the treatment of tumors. Suitable anti-tumor agents include adriamycin, daunomycin, methotrexate, vincristin, 6-mercaptopurine, cytosine arabinoside and cyclophosphamide. Transferrin or ceruloplasmin is preferably coupled to the anti-tumor agent by means of glutaraldehyde.

Abstract: The administration of Factor I and/or Factor H to a mammal has been found to alleviate or prevent such autoimmune diseases as systemic lupus erythematosus, rheumatoid arthritis and glomerulonephritis.

Abstract: Parenteral solutions comprising(a) a sparingly soluble medicament active compound,(b) a solvent consisting of(i) 5-100 M/V % of an organic solvent or of a mixture of organic solvents and(ii) 0-95 W/V % of water,(c) A 0.5-30 W/V % strength aqueous solution of a human serum protein and customary auxiliaries and/or excipients, 1 to 40,000 parts by weight, preferably 25 to 30,000 parts by weight of solvent (b) and 1 to 1,000,000 parts by weight, preferably 50 to 40,000 parts by weight, of human serum protein solution (c) being present per part by weight of medicament active compound.The sparingly soluble medicament active compounds which can be used have a solubility in water of between 1 .mu.g and 10 g, preferably between 10 .mu.g and 1 g per liter of water. Examples of such medicaments are dihydropyridine compounds and pyrazolones, and muzolimine.

Abstract: Method and composition for providing a non-toxic, sterile, virally inactivated human transferrin preparation for use in cell culture systems. The method comprises saturation of the transferrin with an excess of iron, removal of free iron radicals and unwanted proteins, and pasteurization of the iron-bound transferrin substantially free of iron radicals.

Abstract: High purity albumin can be recovered in high yield from human plasma protein solution containing albumin by heat-treatment of the solution to denature and precipitate non-albumin proteins in a combination of specific conditions such as protein concentration of the solution, pH, heating time and temperature, the concentration of precipitant ammonium sulfate.

Abstract: A protein PP.sub.18 is isolated having the following characteristics:(a) an electrophoretic mobility in the region of that of .beta..sub.1 -globulins;(b) an isoelectric point between 5.6 and 6.2;(c) a sedimentation coefficient s.sub.20,w of 5.0.+-.0.2 S;(d) a molecular weight determined in an ultracentrifuge of 82,300.+-.5,600;(e) a carbohydrate fraction of 2.3.+-.1.3 g/100 g (mannose 0.15.+-.0.1, xylose 0.5.+-.0.5, galactose 0.5.+-.0.2, glucose 0.2.+-.0.1, N-acetylglucosamine 0.7.+-.0.2, and N-acetylneuraminic acid 0.25.+-.0.2, each g/100 g).Also described is the amino acid composition of the protein and a process for its isolation. Antiserum is prepared and used in an immunoassay to detect the protein.

Abstract: A fibronectin preparation in the form of an aqueous solution at least upon use is disclosed. The preparation contains at least one member selected from the group consisting of disaccharides, albumin and nonionic surface active agents as a stabilizer. The preparation has improved water-solubility when in use and high stability in an aqueous solution.

Abstract: The protein PP.sub.21 which has the following characteristics:(a) an electrophoretic mobility in the region of that of .beta..sub.1 -globulins,(b) an isoelectric point of 4.6.+-.0.3;(c) a sedimentation coefficient s.sub.20,w of 3.2.+-.0.2 S;(d) a molecular weight determined in an ultracentrifuge of 52,900.+-.6,200;(e) an extinction coefficient E.sub.1 cm.sup.1% (280 nm) of 10.5.+-.1.0; and(f) a carbohydrate fraction of 19.2.+-.5.2 g/100 g (mannose 1.8.+-.0.4, galactose 4.3.+-.1.0, fucose 1.3+0.3, N-acetylglucosamine 6.5.+-.2.0 and N-acetylneuraminic acid 5.3.+-.1.5, each g/100 g),and a specified amino acid composition, a process for obtaining it and its use are described.

Abstract: A method of preparing an anti-breast tumor compound comprised of a toxic metal bound to the blood protein transferrin is disclosed which has superior therapeutic properties. When monomeric transferrin is bound to cis-Dichlorodiammineplatinum (II), a chemotherapeutic agent is produced which specifically attacks and kills rapidly multiplying breast tumor cells without damaging normal cells. In addition, the body's immune defenses against foreign substances are substantially not activated. In preferred embodiments, 1.8-2.2 atoms of platinum are bound to each molecule of transferrin. The platinum-transferrin is prepared by first protecting the sulfhydro groups on essentially iron free transferrin with an excess of cystine in solution. Cis-dichlorodiammine platinum (II) is then reacted with the iron-free transferrin in the presence of bicarbonate anion.

Abstract: A method of preparing an anti-breast tumor compound comprised of a toxic metal bound to the blood protein transferrin is disclosed which has superior therapeutic properties. When monomeric transferrin is bound to cis-Dichlorodiammineplatinum (II), a chemotherapeutic agent is produced which specifically attacks and kills rapidly multiplying breast tumor cells without damaging normal cells. In addition, the body's immune defenses against foreign substances are substantially not activated. In preferred embodiments, 1.8-2.2 atoms of platinum are bound to each molecule of transferrin. The platinum-transferrin is prepared by first protecting the sulfhydro groups on essentially iron free transferrin with an excess of cystine in solution. Cis-dichlorodiamine platinum (II) is then reacted with the iron-free transferrin in the presence of bicarbonate anion.